Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syn-Tech Chem & Pharm CoROCO:1777 +0.54%81 EV-to-EBITDA is 4.34 as of Sep. 22, 2026, which is 46% below its 10-year median of 8.00. GuruFocus rates ROCO:1777 with a GF Score™ of 81/100 and a GF Value™ of NT$97.21 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 430 Biotechnology companies, Syn-Tech Chem & Pharm Co ranks better than 69.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Syn-Tech Chem & Pharm Co's enterprise value is NT$2,455 Mil.
Syn-Tech Chem & Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$566 Mil. Therefore, Syn-Tech Chem & Pharm Co's EV-to-EBITDA for today is 4.34.
The historical rank and industry rank for Syn-Tech Chem & Pharm Co's EV-to-EBITDA or its related term are showing as below:
ROCO:1777'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.14 Med: 8 Max: 17.04
Current: 4.35
During the past 13 years, the highest EV-to-EBITDA of Syn-Tech Chem & Pharm Co was 17.04. The lowest was 4.14. And the median was 8.00.
ROCO:1777's EV-to-EBITDA is ranked better than 69.3% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs ROCO:1777: 4.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Syn-Tech Chem & Pharm Co (ROCO:1777) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Syn-Tech Chem & Pharm Co's PE Ratio (TTM) for today is calculated as:
Syn-Tech Chem & Pharm Co's share price for today is NT$74.30.
Syn-Tech Chem & Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7.417.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1777 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Syn-Tech Chem & Pharm Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syn-Tech Chem & Pharm Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syn-Tech Chem & Pharm Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Syn-Tech Chem & Pharm Co's EV-to-EBITDA falls into.
Syn-Tech Chem & Pharm Co's current Enterprise Value is NT$2,455 Mil.
Syn-Tech Chem & Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$566 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syn-Tech Chem & Pharm Co (ROCO:1777) has a EV-to-EBITDA of 4.34 as of Sep. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Syn-Tech Chem & Pharm Co. This is 46% below median its historical median of 8.00. Over the past decade, Syn-Tech Chem & Pharm Co's EV-to-EBITDA has ranged from 4.14 to 17.04. According to the industry distribution chart, Syn-Tech Chem & Pharm Co ranks #132 out of 430 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Syn-Tech Chem & Pharm Co's EV-to-EBITDA too high?
Syn-Tech Chem & Pharm Co's current EV-to-EBITDA of 4.34 is 46% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 4.14 to a high of 17.04. The Biotechnology industry median EV-to-EBITDA is 13.02. Syn-Tech Chem & Pharm Co's value of 4.34 is 66.7% below this industry median. Based on the distribution chart, Syn-Tech Chem & Pharm Co ranks #132 out of 430 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Syn-Tech Chem & Pharm Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syn-Tech Chem & Pharm Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn-Tech Chem & Pharm Co ranks #132 out of 430 companies for EV-to-EBITDA. This puts Syn-Tech Chem & Pharm Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.02. Syn-Tech Chem & Pharm Co's value of 4.34 is 66.7% below this benchmark. Historically, Syn-Tech Chem & Pharm Co's own EV-to-EBITDA has ranged from 4.14 to 17.04 over the past decade. While the company's 10-year median is 8.00 vs. the industry median of 13.02, Syn-Tech Chem & Pharm Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syn-Tech Chem & Pharm Co's current EV-to-EBITDA of 4.34 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Syn-Tech Chem & Pharm Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syn-Tech Chem & Pharm Co's current EV-to-EBITDA is 4.34, which is 46% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn-Tech Chem & Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co (ROCO:1777) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$97.21, compared to a current price of NT$74.30 — trading 23.6% below its estimated fair value. The current EV-to-EBITDA is 4.34, which is 46% below median its 10-year median of 8.00 and 66.7% below the Biotechnology industry median of 13.02. Syn-Tech Chem & Pharm Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Syn-Tech Chem & Pharm Co (ROCO:1777), the current EV-to-EBITDA is 4.34 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syn-Tech Chem & Pharm Co (ROCO:1777) Overvalued in 2026?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co stock appears to be undervalued.
The current stock price of NT$74.30 is trading 23.6% below its estimated GF Value™ of NT$97.21.
GuruFocus considers Syn-Tech Chem & Pharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:1777:
EV-to-EBITDA: 4.34 (46% below median its 10-year median of 8.00)
GF Value™: NT$97.21 vs. price of NT$74.30 (23.6% below fair value)
Industry Position: 66.7% below the Biotechnology median (#132 of 430)
No single metric tells the full story. See the ROCO:1777 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syn-Tech Chem & Pharm Co Ltd is engaged in the manufacture and sale of western medicines, veterinary drugs, food additives, cosmetics, and related businesses. It manufactures and sells Active Pharmaceutical Ingredients for domestic and foreign pharmaceutical companies and trade agents. Its products include Alfuzosin HCl, Atomoxetine HCl, Chlorzoxazone, Chlormezanone, Cloperastine HCl, Crotamiton, Diclofenac Epolamine, and others. It generates the majority of its revenue from Asia excluding Taiwan.
81GF Score
Get the complete analysis for ROCO:1777
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1777 has been successfully added to your 
